Articles related to AMD/MACULAR DEGENERATION

OCT angiography revealed subclinical retinal and choroidal blood flow changes that correlated with disease severity across diabetic retinopathy, AMD, and central serous retinopathy in cited studies.

CPT code 0936T became active in January 2025 for retinal photobiomodulation, with reimbursement determined claim-by-claim and scope-of-practice limits restricting who may perform the procedure.

FDA approval of 20‑week dosing for Eylea HD offers eligible wAMD and DME patients the potential for fewer injections while maintaining long‑term visual outcomes.

“Axpaxli is the first and only investigational product in wet AMD with a novel mechanism of action to successfully demonstrate superiority to an approved anti-VEGF agent since their initial approval more than 20 years ago.” — Pravin U. Dugel, MD, Ocular Therapeutix

More than 80% of the patients were able to read letters and words, and some of them are reading pages in a book.

“This genetic overlap suggests that there may be shared biological pathways or metabolic mechanisms connecting the preference for instant coffee with the risk of developing dry AMD.”